 |
|
epratuzumab
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | AMG 412
Humanized Anti-CD22 Monoclonal Antibody IgG1
LL2
monoclonal antibody LL2 | | | | US brand name: | | LymphoCide | | | | Abbreviations: | | hLL2
MOAB LL2 | | |
|
|
